Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers
ConclusionSix cycles of TEC with prophylactic G-CSF is an effective and tolerable neoadjuvant regime for HER2-negative breast cancers. Hematological toxicities were the most common toxicities. Although many patients required dose reduction, all patients completed treatment and there was no observed cardiotoxicity. (Source: Advances in Therapy)
Source: Advances in Therapy - October 26, 2021 Category: Drugs & Pharmacology Source Type: research

Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost –Utility Analysis
ConclusionBOT was cost-effective compared to no treatment for both the induction and maintenance of clinico-pathological remission of EoE in patients non-responsive to PPIs. (Source: Advances in Therapy)
Source: Advances in Therapy - October 26, 2021 Category: Drugs & Pharmacology Source Type: research

Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study
ConclusionIn clinical practice, tolvaptan improved serum sodium and decreased hyponatremia symptoms in hyponatremia secondary to SIADH. Serum sodium should be monitored during treatment to minimize risk of rapid correction.Trial RegistrationClinicaltrials.gov identifier NCT01228682. (Source: Advances in Therapy)
Source: Advances in Therapy - October 25, 2021 Category: Drugs & Pharmacology Source Type: research

The Contribution of Galenics to Patients ’ Sensory Perception of Nasal Sprays After Nasal Surgery: Data from a Prospective Randomised, Controlled, Double-Blind, Crossover, Multicentre Study
ConclusionThe overall sensory perception of both nasal sprays was evaluated comparably well in patients after nasal surgery and overall the application of the new galenics nasal spray was preferred by significantly more patients compared to the comparator nasal spray. Patients with marked nasal abnormalities may have a greater benefit from the contribution of galenics as significant differences in the sensory evaluation by the nasal spray sensoric scale in favour of the new galenics product were shown for this subgroup.Trial RegistrationThe current study was registered in the EU Clinical Trials Register with the EudraCT No...
Source: Advances in Therapy - October 24, 2021 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States
ConclusionsThis analysis demonstrated that maintenance therapy with avelumab plus BSC may be a cost-effective option for patients with advanced or metastatic urothelial carcinoma at a willingness-to-pay (WTP) threshold of $150,000/QALY, especially for patients with PD-L1-positive status. (Source: Advances in Therapy)
Source: Advances in Therapy - October 24, 2021 Category: Drugs & Pharmacology Source Type: research

The Preliminary Outcome of Laser-Assisted Angioplasty Combined with Endovascular Radiofrequency Ablation for Thromboangiitis Obliterans
This study aimed to investigate the outcome of LA combined with RFA for TAO.MethodsSixteen consecutive patients underwent LA and RFA procedures between June 2018 and March 2019 in this prospective pilot study. The clinical outcomes and complications were assessed at 6, 12, and 18  months after the procedure. The primary endpoint was defined as the limb salvage rate and freedom of target-lesion revascularization (f-TLR) of the limb, and the effect on the outcome was assessed by the ankle brachial index (ABI), numerical rating scores (NRSs), and the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D).ResultsMen ...
Source: Advances in Therapy - October 22, 2021 Category: Drugs & Pharmacology Source Type: research

Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia
ConclusionOur data support a new paradigm that TKIs may be the first treatment option in selected patients with locally advanced metastatic MTC, followed by locoregional treatment with surgery and/or external beam radiotherapy. Further studies are required to consolidate the presented data. (Source: Advances in Therapy)
Source: Advances in Therapy - October 21, 2021 Category: Drugs & Pharmacology Source Type: research

Selective Mediastinal Lymphadenectomy or Complete Mediastinal Lymphadenectomy for Clinical Stage I Non-Small Cell Lung Cancer: A Meta-Analysis
AbstractIntroductionSelective mediastinal lymphadenectomy (SML) and complete mediastinal lymphadenectomy (CML) are two main types of surgery conducted for the treatment of non-small cell lung cancer (NSCLC) plus lobectomy or segmentectomy. It is not known whether stage I NSCLC can benefit from CML. Using the meta-analytical method, our research aimed to find out the worth of SML and CML for the therapy of clinical stage I NSCLC.MethodsWe searched PubMed, Ovid, MEDLINE, Cochrane Controlled Trial Register (CENTRAL), Embase, and Google Scholar for literature published up to June 2021 to evaluate the comparative research and t...
Source: Advances in Therapy - October 20, 2021 Category: Drugs & Pharmacology Source Type: research

Incidence and Mortality of Malignant Melanoma in Relation to Dermatologist Density in Bavaria
ConclusionThe dermatologist density in Bavaria correlates positively with the incidence of malignant melanoma. Despite an increased incidence, mortality was not elevated in the respective administrative regions. (Source: Advances in Therapy)
Source: Advances in Therapy - October 19, 2021 Category: Drugs & Pharmacology Source Type: research

Sedation Effects Produced by a Ciprofol Initial Infusion or Bolus Dose Followed by Continuous Maintenance Infusion in Healthy Subjects: A Phase 1 Trial
ConclusionCiprofol has potential for clinical application for continuous intravenous infusion to maintain sedation for 12  h with the same safety, tolerability and efficacy as propofol. (Source: Advances in Therapy)
Source: Advances in Therapy - October 19, 2021 Category: Drugs & Pharmacology Source Type: research

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
AbstractSecond-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase  I inhibitor) was the only drug approved by the United States (US) Food and Drug Administration (FDA) for the management of ES-SCLC following progression after first-line treatment with etoposide plus a platinum derivative (EP; carboplatin preferred). With the most recent approval of EP plus a prog rammed death ligand 1 (PD-L1) inhibitor, there are now more therapeutic options...
Source: Advances in Therapy - October 19, 2021 Category: Drugs & Pharmacology Source Type: research

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
This study evaluated risks of recurrent VTE, major bleeding (MB), and clinically relevant non-major bleeding (CRNMB) among older patients with VTE initiating apixaban or warfarin stratified by demographics and SES.MethodsAdult patients ( ≥ 65 years) who initiated apixaban or warfarin after a VTE event were selected from the US CMS Medicare database (September 2014–December 2017). Stabilized inverse probability treatment weighting (IPTW) was used to balance patient characteristics between treatment cohorts. Patients were strat ified by age, gender, race, and SES. For each subgroup, Cox proportional haza...
Source: Advances in Therapy - October 19, 2021 Category: Drugs & Pharmacology Source Type: research

The Effect of Diquafosol Ophthalmic Solution on Clinical Parameters and Visual Function in Soft Contact Lens-Related Dry Eye
This study evaluated the efficacy and safety of diquafosol ophthalmic solution (DQS) in soft contact lens (SCL)-related dry eye using artificial tear as a control.MethodsThis study enrolled 26 patients with SCL-related dry eye. DQS and artificial tears (AT) were instilled into the right and left eyes, respectively, with their SCLs on. Dry eye examinations (including tear film breakup time, tear volume, and staining score) were performed and visual function (including contrast sensitivity) was also evaluated before (at baseline) and after treatment (at 4- and 8-week examinations). Subjective symptoms were assessed separatel...
Source: Advances in Therapy - October 19, 2021 Category: Drugs & Pharmacology Source Type: research

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor  + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
AbstractIntroductionSingle-agent belantamab mafodotin (belamaf; BLENREP) demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma and  ≥ 3 prior lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody (DREAMM-2; NCT03525678).MethodsAt the time of this study, STORM Part 2, NCT02336815 (selinexor plus low-dose dexamethasone; sel  + dex) was systematically identified as the only feasible comparator to the DREAMM-2 cohort. Matching-adjusted indirect comparisons (MAIC) evaluated efficacy and safety of belamaf (2.5&nbs...
Source: Advances in Therapy - October 19, 2021 Category: Drugs & Pharmacology Source Type: research

AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol
AbstractIntroductionThe safety and efficacy of both abobotulinumtoxinA and onabotulinumtoxinA for upper limb spasticity are well established, but head-to-head comparisons are lacking.MethodsDIRECTION is an international, randomized, double-blind, crossover study comparing the safety and efficacy of abobotulinumtoxinA with onabotulinumtoxinA in the management of upper limb spasticity at doses at or near maximum recommended in product labelling. Participants (18 –75 years) will be randomized (1:1) to either one cycle of abobotulinumtoxinA (900U) followed by onabotulinumtoxinA (360U) or vice versa. To maintain blin...
Source: Advances in Therapy - October 19, 2021 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States
ConclusionsOn the basis of a willingness-to-pay threshold of $150,000, nivolumab plus cabozantinib was not cost-effective under current drug pricing in the first-line treatment of advanced RCC from a US payer ’s perspective. (Source: Advances in Therapy)
Source: Advances in Therapy - October 18, 2021 Category: Drugs & Pharmacology Source Type: research

Non-Surgical Treatments for Keratinocyte Carcinomas
This article reviews commonly utilized nonsurgical options such as cryotherapy, photodynamic therapy, topical treatments, and radiation as well as systemic treatments including immunotherapies and chemotherapies. (Source: Advances in Therapy)
Source: Advances in Therapy - October 15, 2021 Category: Drugs & Pharmacology Source Type: research

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
ConclusionIn the short and long term, upadacitinib combination therapy versus tofacitinib combination therapy and upadacitinib monotherapy versus methotrexate monotherapy were associated with significantly lower direct medical costs for patients with RA.Trial RegistrationClinicalTrials.gov identifier, NCT02675426, NCT02706951, and NCT00853385. (Source: Advances in Therapy)
Source: Advances in Therapy - October 12, 2021 Category: Drugs & Pharmacology Source Type: research

Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia
In this study we aimed to characterize the progression of hyperkalemia and identify the risk factors for hyperkalemia progression.MethodsAdults with mild hyperkalemia (at least one serum potassium measure  >  5.0 and ≤ 5.5 mEq/L) were identified using electronic medical records from the Research Action for Health Network (2012–2018). Progression to moderate-to-severe and progression to severe hyperkalemia were defined as the first occurrences of a serum potassium measure >  5.5 and>  6.0 mEq/L, respectively. Kaplan–Meier analyses were conducted to ...
Source: Advances in Therapy - October 7, 2021 Category: Drugs & Pharmacology Source Type: research

Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17
ConclusionOur data suggest that CT-P17 may be used without any significant loss of stability when stored at 5  °C or 25 °C with 60% relative humidity for up to 28 days, and was not impacted by protein concentration tested and delivery device. Comparative stability data suggest that the appropriate maximum storage period for CT-P17 may be up to 28 days at room temperature with 60% relative humidity. (Source: Advances in Therapy)
Source: Advances in Therapy - October 7, 2021 Category: Drugs & Pharmacology Source Type: research

Inpatient Hospital Costs for COVID-19 Patients in the United States
ConclusionThe burden from COVID-19 in terms of hospital and ICU costs and LOS has been substantial, though significant decreases in cost and LOS and increases in the share of hospital discharges to home were observed from April to December 2020. These estimates will be useful for inputs to economic models, disease burden forecasts, and local healthcare resource planning. (Source: Advances in Therapy)
Source: Advances in Therapy - October 5, 2021 Category: Drugs & Pharmacology Source Type: research

Variability in Contraceptive Clinical Trial Design and the Challenges in Making Comparisons Across Trials
AbstractClinical trials of contraceptives have often differed in their study designs, making cross-trial comparisons difficult. This brief report outlines some of the technical design features that can vary from trial to trial. For example, the overall number of menstrual cycles in a study has substantial impact on the final efficacy determination; however, the rules related to qualifying cycles can differ based on the length of the study and the statistical analysis plan. In two commonly used methods of calculating efficacy, the Pearl Index and the time-to-event analysis, inclusion of fewer menstrual cycles results in hig...
Source: Advances in Therapy - September 23, 2021 Category: Drugs & Pharmacology Source Type: research

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
AbstractIntroductionResults from the open-label extension of the phase  3b CONQUER trial are presented to evaluate the effectiveness and safety of galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide, for up to 6 months in patients with multiple prior migraine preventive treatment failures.MethodsPatients were 18 –75 years old with episodic or chronic migraine and 2–4 standard-of-care migraine preventive medication category failures. After 3 months of randomized treatment with galcanezumab (120 mg/month with 240 mg loading dose;n = 232) or pla...
Source: Advances in Therapy - September 20, 2021 Category: Drugs & Pharmacology Source Type: research

Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase  3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)
ConclusionRoxadustat was non-inferior to ESAs in maintaining hemoglobin levels in this cohort of patients with anemia of CKD on dialysis for at least 4  months who were previously treated with ESAs. Observed TEAEs were consistent with previous studies. (Source: Advances in Therapy)
Source: Advances in Therapy - September 19, 2021 Category: Drugs & Pharmacology Source Type: research

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
AbstractBackgroundIn the absence of head-to-head trials, we performed an indirect treatment comparison of the β3-adrenergic agonists vibegron and mirabegron in the treatment of overactive bladder (OAB).MethodsPubMed, Embase, and Cochrane Library were searched for articles related to phase  3, double-blind, controlled trials of vibegron 75 mg and mirabegron 25/50 mg in patients with OAB. Efficacy outcomes included change from baseline at weeks 4, 12, and 52 in mean daily number of total urinary incontinence episodes and micturitions and mean volume voided/micturition. Effect size was computed as pla...
Source: Advances in Therapy - September 18, 2021 Category: Drugs & Pharmacology Source Type: research

Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial
ConclusionIn patients with moderate-to-severe COPD and CV risk factors, the addition of aclidinium to maintenance therapy with LABA or LABA  + ICS provided further benefit.Trial RegistrationClinicalTrials.gov identifier NCT01966107. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2021 Category: Drugs & Pharmacology Source Type: research

Application of Artificial Intelligence in Acute Coronary Syndrome: A Brief Literature Review
AbstractArtificial intelligence (AI) is defined as a set of algorithms and intelligence to try to imitate human intelligence. Machine learning is one of them, and deep learning is one of those machine learning techniques. The application of AI in healthcare systems including hospitals and clinics has many possible advantages and future prospects. Applications of AI in cardiovascular medicine are machine learning techniques for diagnostic procedures including imaging modalities and biomarkers and predictive analytics for personalized therapies and improved outcomes. In cardiovascular medicine, AI-based systems have found ne...
Source: Advances in Therapy - September 15, 2021 Category: Drugs & Pharmacology Source Type: research

Effectiveness of Safinamide over Mood in Parkinson ’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
AbstractIntroductionMood disorders are frequent in Parkinson ’s disease (PD) and a favorable effect of safinamide on mood has been observed. We aimed to analyze the effectiveness of safinamide on mood as a secondary objective from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR symptoms in patients with Parkinson’s di sease) study.MethodsSAFINONMOTOR is a prospective open-label single-arm study conducted in five centers from Spain. Patients with PD were required to have at baseline a Non-Motor Symptoms Scale (NMSS) total score of at least 40. In this analysis, the changes f...
Source: Advances in Therapy - September 15, 2021 Category: Drugs & Pharmacology Source Type: research

Pharmacotherapy for the Treatment of Gastric Antral Vascular Ectasia: A Narrative Review
AbstractGastric antral vascular ectasia (GAVE) is an uncommon clinical entity leading to recurrent gastrointestinal bleeding. There is no consensus regarding treatment of GAVE. Endoscopic therapy is the preferred treatment option, but has a fairly high recurrence rate. Surgical resection can completely resolve GAVE, but is invasive with a relatively high risk of postoperative complications. Recently, the role of pharmacotherapy for GAVE has been recognized. However, the evidence is limited to scattered case reports or small case series. This review comprehensively summarizes the efficacy and side effects of drugs commonly ...
Source: Advances in Therapy - September 15, 2021 Category: Drugs & Pharmacology Source Type: research

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
ConclusionRoxadustat improved hemoglobin similarly to ESA while demonstrating comparable cardiovascular and overall safety profiles in a wide spectrum of dialysis-dependent patients with anemia of CKD. Roxadustat represents an oral alternative to ESAs for achieving a target hemoglobin for anemia of CKD in dialysis-dependent patients. (Source: Advances in Therapy)
Source: Advances in Therapy - September 14, 2021 Category: Drugs & Pharmacology Source Type: research

Health Care Costs in Patients with and without Secondary Hyperparathyroidism  in Spain
ConclusionsThese results show that sHPT is associated with substantially higher costs of both, pharmacological treatments and associated CVEs. Preventing the development of sHPT with early management in the course of CKD could possibly lead to better health outcomes and cost balance for health care systems. (Source: Advances in Therapy)
Source: Advances in Therapy - September 14, 2021 Category: Drugs & Pharmacology Source Type: research

Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis
ConclusionThis analysis of real-world claims data showed that uninterrupted TIM use was not associated with an increased likelihood of hospitalizations, ED visits, or negative respiratory outcomes compared to interrupted TIM use among patients with immune-mediated conditions, regardless of COVID-19 diagnosis. (Source: Advances in Therapy)
Source: Advances in Therapy - September 13, 2021 Category: Drugs & Pharmacology Source Type: research

Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications
AbstractBotulinum neurotoxins (BoNTs) are proteins produced by bacteria of theClostridium family. Upon oral ingestion, BoNT causes the neuroparalytic syndrome botulism. There are seven serotypes of BoNT (serotypes A-G); BoNT-A and BoNT-B are the botulinum toxin serotypes utilized for therapeutic applications. Treatment with BoNT injections is used to manage chronic medical conditions across multiple indications. As with other biologic drugs, immunogenicity after long-term treatment with BoNT formulations may occur, and repeated use can elicit antibody formation leading to clinical nonresponsiveness. Thus, approaching BoNT ...
Source: Advances in Therapy - September 13, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States
(Source: Advances in Therapy)
Source: Advances in Therapy - September 13, 2021 Category: Drugs & Pharmacology Source Type: research

Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations
ConclusionsA POPPK model was successfully developed for LCPT in de novo kidney recipients. The model could guide a personalised dosing strategy early after transplantation. For the model to be translated into clinical practice, its beneficial impact of earlier attainment of therapeutic trough levels should be demonstrated on hard clinical outcomes in further studies. (Source: Advances in Therapy)
Source: Advances in Therapy - September 12, 2021 Category: Drugs & Pharmacology Source Type: research

Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review
ConclusionNK3Ras trials show encouraging efficacy and tolerability/safety. Completion of phase 3 NK3Ra trials are required to confirm efficacy and uphold safety/tolerability data but phase 2 results suggest that NK3Ras are more effective than SNRIs for non-hormonal treatment of menopausal HFs. (Source: Advances in Therapy)
Source: Advances in Therapy - September 12, 2021 Category: Drugs & Pharmacology Source Type: research

Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer ’s Dementia: A 48-Week Real-World Observational Study
ConclusionsThe use of the 10  cm2 rivastigmine patch in the mild stage of AD maintained cognitive function at Week 24 and neuropsychiatric function at Week 48. The treatment persistency and safety profile support the clinical tolerability of the rivastigmine patch in the management of mild-to-moderate AD in Taiwan. (Source: Advances in Therapy)
Source: Advances in Therapy - September 10, 2021 Category: Drugs & Pharmacology Source Type: research

Health-Related and Economic Burden Among Family Caregivers of Patients with Acute Myeloid Leukemia or Hematological Malignancies
ConclusionFindings indicate a need for additional research, public health approaches to support FCs, and effective interventions to address FC burden. Minimizing FC burden and improving quality of life may reduce the overall healthcare service use and allow FCs to more effectively fulfill caregiver tasks. Support systems to alleviate caregiver burden may create reinforced integrators, thus positively affecting quality of life and possibly the outcomes of patients. (Source: Advances in Therapy)
Source: Advances in Therapy - September 9, 2021 Category: Drugs & Pharmacology Source Type: research

Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study
ConclusionsIn this study of patients cycling on SC-TNFis in IA, persistence was greater in second- compared to first-line treatment. The finding was consistent across all IA indications. Hence, patients who discontinue their first-line treatment may still benefit from treatment with an alternative SC-TNFi as a second-line therapy in IA. (Source: Advances in Therapy)
Source: Advances in Therapy - September 3, 2021 Category: Drugs & Pharmacology Source Type: research

Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
AbstractIntroductionAlthough several studies have shown that a simplified cardiovascular drug treatment leads to better treatment adherence, limited and conflicting findings have been reported on the separate or single-pill combination of the now recommended association between a statin and ezetimibe. We addressed this issue in a large cohort of patients newly treated with statins to whom ezetimibe was additionally administered, either separately or as a single-pill combination.MethodsA total of 256,012 patients (age 40 –80 years) from the Lombardy Region (Italy) newly treated with statins during 2011–2013...
Source: Advances in Therapy - September 3, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
(Source: Advances in Therapy)
Source: Advances in Therapy - September 3, 2021 Category: Drugs & Pharmacology Source Type: research

Myths and Truths about Placebo Effect in Rehabilitation for Musculoskeletal Pain
AbstractThis commentary provides the authors ’ point of view about the biopsychosocial perspective of placebo effect on musculoskeletal pain in the rehabilitation field. (Source: Advances in Therapy)
Source: Advances in Therapy - September 2, 2021 Category: Drugs & Pharmacology Source Type: research

Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial
ConclusionThese results support the validity, reliability and sensitivity to change of the P-SIM in assessing key symptoms (itching, skin pain and scaling) in patients with moderate to severe plaque psoriasis.Trial registrationNCT03536884. (Source: Advances in Therapy)
Source: Advances in Therapy - September 2, 2021 Category: Drugs & Pharmacology Source Type: research

Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant
ConclusionsIn this real-world study, suvorexant initiation was associated with immediate and continued decreases in HCRU and costs in insomnia patients. Further research is needed to understand the effect of suvorexant initiation on direct medical costs as well as costs associated with lost productivity in other real-world settings. (Source: Advances in Therapy)
Source: Advances in Therapy - August 31, 2021 Category: Drugs & Pharmacology Source Type: research

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
The objective of this study was to characterize migraine-specific quality of life version 2.1 (MSQv2) scores and corresponding mapped EuroQol-5 Dimensions-3 Level (EQ-5D-3L) utility values.MethodsStudy participants were randomized into two treatment regimens: individuals with 2 –14 MMD received rimegepant 75 mg as needed (PRN), and those with 4–14 MMD at baseline who received rimegepant on a fixed every-other-day schedule plus an as needed dose on days they did not treat (QOD + PRN). MSQv2 was mapped to EQ-5D-3L utilities using a validated algorithm. Outcomes were a ssessed for the PRN arm at bas...
Source: Advances in Therapy - August 29, 2021 Category: Drugs & Pharmacology Source Type: research

Comparison of the Effect and Complications of Sequential Bilateral Arthroplasty at Different Time Intervals and Simultaneous Bilateral Total Knee Arthroplasty: A Single-Centre Retrospective Cohort Study
AbstractIntroductionTo the authors' knowledge, there is no current consensus regarding the optimal interprocedural interval for patients who have undergone bilateral total knee arthroplasty (BTKA). The purpose of this study is to evaluate complication rates and functional outcome in patients who have undergone BTKA (simultaneous or sequential at different time intervals), and to determine an optimal time frame for the second knee.MethodsData from 315 patients who were able to tolerate simultaneous BTKA according to the anaesthesiologist ’s preoperative assessment between 2016 and 2020 were analysed retrospectively. A...
Source: Advances in Therapy - August 28, 2021 Category: Drugs & Pharmacology Source Type: research

Experimental and Compassionate Drug Use During the First Wave of the COVID-19 Pandemic: A Retrospective Single-Center Study
The objective of this study was to study the relationship between patient severity, the number of experimental/compassionate medications received (main outcome measure), and patient outcomes [survival to hospital discharge and length of hospital stay (LOS)].MethodsRetrospective analysis of data collected in real time during the first pandemic wave in a tertiary care hospital. Data included patient demographics, comorbidities, admission vital signs, laboratory values, most extreme respiratory intervention during hospitalization, and data regarding treatment with compassionate/experimental drugs during their stay.ResultsOver...
Source: Advances in Therapy - August 22, 2021 Category: Drugs & Pharmacology Source Type: research

H ürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis
ConclusionThis review serves to further elucidate the main characteristics of this malignancy. HCC of the thyroid is rare and most often presents with a relatively large nodule, whereas lymph node metastases are rare. Given the rarity of HCC, a consensus on their treatment is needed, as doubts remain concerning the role of specific tumor findings and their influence on management. (Source: Advances in Therapy)
Source: Advances in Therapy - August 22, 2021 Category: Drugs & Pharmacology Source Type: research

The High Expression of RRM2 Can Predict the Malignant Transformation of Endometriosis
AbstractIntroductionA large number of epidemiological studies have revealed that women with endometriosis (EMS) have a higher risk of developing endometriosis-associated ovarian cancer (EAOC). At present, there are few studies on predicting the malignant transformation of ovarian endometriosis (OE). The purpose of this study is to identify and verify the molecules that may be able to predict the malignant transformation of OE.MethodsThe gene expression profiles of ovarian cancer and OE were downloaded from Gene Expression Omnibus (GEO), and a common hub gene ribonucleotide reductase M2 (RRM2) was identified. A total of 44 ...
Source: Advances in Therapy - August 21, 2021 Category: Drugs & Pharmacology Source Type: research

Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine
AbstractRecent network meta-analyses support the use of pharmacotherapy in patients with generalised anxiety disorder (GAD). Compared with placebo, drug treatment can improve symptoms and quality of life, and is more effective in preventing relapse. Selective serotonin reuptake inhibitors and serotonin –norepinephrine reuptake inhibitors are generally considered the first-line agents of choice in GAD, but in some patients, an alternative evidence-based treatment with a different mechanism of action may also be considered (e.g. those with severe GAD, inadequate response, adverse effects and/or co ntraindications). One...
Source: Advances in Therapy - August 21, 2021 Category: Drugs & Pharmacology Source Type: research